“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin's IPMG is responsible for creating, securing, and leveraging a portfolio of high-value patents, products, and research pipeline projects. IPMG has also successfully managed patent challenges in courts and patent offices around the world.
In FY2019, the company was first-to-file with respect to generic versions of Spiriva® DPI, Jublia® Topical Solution, Kerydin® Topical Solution, Jardiance® Tablets, Glyxambi® Tablets, Esbriet® Capsules, Esbriet® Tablets, Zarelto® Tablets 2.5mg, Invokamet® XR Tablets ER, Plenvu® Oral solution, and Clenpiq® Oral Solution. Lupin's number of first to file products pending launch now stands at 40.
Cumulative ANDA and NDA filings with U.S. FDA now stand at 402, with 239 approvals as of FY2018. Lupin has a total of 36 first-to-file ANDAs pending launch, which includes 15 exclusive first-to-file opportunities.
In FY2019, the company settled 13 pending U.S patent litigations and received favourable decisions on Prepopik® (US) and Truvada® (UK and Germany).
The Company filed 159 patent applications. The cumulative number of patent applications filed by Lupin in India and other countries currently stands at 3,204. The patent applications filed in FY 2019 included 33 formulation patent applications, 52 API patent applications, 9 biotech patent applications and 65 NDDD patent applications. We have successfully secured 64 patents, including 31 NDDD patents during FY 2019.